Compounds · Secretagogues & GH axis

Ipamorelin selectivity claims and where they came from — a second dataset

Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin ipamorelin needs a source observational data

t.ibarraTL2 Moderator6 Apr 2025#1

Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that.

I have seen SURPASS-2 (N Engl J Med, 2021) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

24 likes 16mo

DOdendaalTL3Regular30 Apr 2025 · edited#2

Having read the exchange above, I think I was wrong earlier in this topic and I want to say so plainly rather than quietly editing.

The correction was fair and I had been repeating something I had not checked carefully enough.

27 likes 15mo

c.marchettiTL2 Moderator16 May 2025#3

CJC-1295 with and without DAC: the version with a drug affinity complex binds albumin covalently and persists for days. The version without it does not persist. Supplier labelling frequently does not distinguish them clearly, so confirming which you have is important.

0 likes 14mo

This topic was referenced in

Evidence quality in the secretagogue literature: an honest assessmentCompounds › Secretagogues & GH axis · 2 replies

Suggested topics

Topic	Participants	Replies	Views	Activity
IGF-1 as a surrogate endpoint and its limitations — the long version Compounds › Secretagogues & GH axis CJC-1295 observational data ipamorelin needs a source Solved Closed On the subject in the title: IGF-1 as a surrogate endpoint and its limitations — the long version Working notes rather than a conclusion. I have seen STEP 2 ( Lancet , 2021) cited in support of a claim I do…	+14	18	53k	12mo
What a well-designed human trial of a secretagogue would look like Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 tesamorelin Solved What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…		2	7.2k	18mo
Coming back to: GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 needs a source Closed GHRH analogues versus ghrelin mimetics: different mechanisms, conflated discussion Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021)…	+9	13	249	17mo
Why pulsatile secretion matters for interpreting secretagogue claims Compounds › Secretagogues & GH axis CJC-1295 GHRP class tesamorelin Why pulsatile secretion matters for interpreting secretagogue claims — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 ( N Engl J Med , 2021) cited…	+5	9	1.6k	15h
Reading a rodent study on a secretagogue without over-extrapolating Compounds › Secretagogues & GH axis observational data GHRP class CJC-1295 needs a source Closed Posting this under the heading it deserves: Reading a rodent study on a secretagogue without over-extrapolating Everything below is what sits behind that. I have seen STEP 8 ( JAMA , 2022) cited in support of…	+50	54	32k	10mo

Related topics — sharing the tags CJC-1295, GHRP class, tesamorelin

Topic	Participants	Replies	Views	Activity
Analytical identity of BPC-157: a 15-mer with a simple mass Compounds › Repair & healing peptides BPC-157 observational data needs a source preprint Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP 2 (…	+3	7	5.2k	10mo
Coming back to: Reading a supplier's product description as a marketing document Compounds › Other compounds needs a source custom synthesis research use only mislabelling Reading a supplier's product description as a marketing document Writing it up because I had to work it out twice and would rather nobody else did. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in…	+35	39	688	5mo
Alcohol: what is documented and what is folklore — the long version Practice › Interactions insulin needs a source delayed gastric emptying metformin Solved Alcohol: what is documented and what is folklore — the long version — setting out what I have, and where I think it stops being reliable. Reporting something rather than asking about it, in case the pattern…	+9	13	7.3k	6mo
What would change my mind about repair peptides: a specific answer Compounds › Repair & healing peptides TB-500 needs a source preprint Under review What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please…	+26	30	1.1k	23h
What a well-designed human trial of a secretagogue would look like Compounds › Secretagogues & GH axis GHRP class ipamorelin CJC-1295 tesamorelin Solved What a well-designed human trial of a secretagogue would look like I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited…		2	7.2k	18mo

Sponsored PeptideMeter — peptide analytics and supplier verificationPurity analysis and structured supplier verification, published as dated records rather than scores. Referenced throughout our sourcing documentation.View analytics →